Rare Disease Trial, By Invitation NCT04681781 Sponsor: TESS Research Foundation Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, By Invitation

NCT04681781
By Invitation Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A parent, legal guardian, or the patient themselves must be willing and able to give their agreement to take part in the study
  • Both males and females of any age can apply
  • The patient must have a suspected or confirmed diagnosis of SLC13A5 deficiency (a rare genetic condition), meaning they have changes in both copies of the SLC13A5 gene along with matching symptoms — patients with uncertain genetic results may still qualify if their doctor and the study team think they are a good candidate (confirm with trial site)
  • The patient and their caregiver must be willing to share medical information and take part in standardized tests and assessments

Who may not be able to join:

  • People who have been confirmed to have a second, separate condition — whether genetic or not — that affects brain development or causes symptoms that overlap with SLC13A5 deficiency

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
TESS Research Foundation
Registry
ClinicalTrials.gov
Start date
1 March 2021
Est. completion
31 December 2023

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

SLC13A5 deficiency motor scale assessments.; Developmental assessment at baseline and longitudinally using Vineland 3; Seizure burden and semiology

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov